PARP1 Deficiency Reduces Tumour Growth by Decreasing E2F1 Hyperactivation: A Novel Mechanism in the Treatment of Cancer

SIMPLE SUMMARY: PARP1 is one of the best characterized enzymes in DNA repair and an attractive target for drug design in cancer therapies. Beyond repair, PARP1 modulates the activity of several transcription factors, of which E2F1 stands out given its critical role in cell cycle regulation. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Iglesias, Pablo, Seoane, Marcos, Golán, Irene, Castro-Piedras, Isabel, Fraga, Máximo, Arce, Víctor M., Costoya, Jose A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599842/
https://www.ncbi.nlm.nih.gov/pubmed/33050515
http://dx.doi.org/10.3390/cancers12102907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599842/
https://www.ncbi.nlm.nih.gov/pubmed/33050515
http://dx.doi.org/10.3390/cancers12102907

Ejemplares similares